Animal Models and Experimental Medicine (Apr 2023)

A new method for preparing a rat intracerebral hemorrhage model by combining focused ultrasound and microbubbles

  • Yao He,
  • Jie Yang,
  • Fengying Hu,
  • Min Liao,
  • Yuru Nie,
  • Xiaoxia Zhu,
  • Tao Zhang,
  • Keer Song,
  • Qinxi Li,
  • Xiaojie Li,
  • Chenghan Mei,
  • Zhe Wu,
  • Qiang Lu,
  • Zhihui Zhong

DOI
https://doi.org/10.1002/ame2.12303
Journal volume & issue
Vol. 6, no. 2
pp. 103 – 110

Abstract

Read online

Abstract Background We aimed to prepare a non‐invasive, reproducible, and controllable rat model of intracerebral hemorrhage with focused ultrasound (FUS). Methods A rat intracerebral hemorrhage (ICH) model was established by combining FUS and microbubbles (μBs), and edaravone was used to verify whether the free radical scavenger had a protective effect on the model. The brain tissue of each group was sectioned to observe the gross histology, blood–brain barrier (BBB) permeability, cerebral infarction volume, and histopathological changes. Results Compared with the FUS group, the BBB permeability was significantly increased in the FUS + μBs (F&B) group (p = 0.0021). The second coronal slice in the F&B group had an obvious hemorrhage lesion, and the FUS + μBs + edaravone (F&B&E) group had smaller hemorrhage areas; however, ICH did not occur in the FUS group. The cerebral infarction volume in the F&B group was significantly larger than that in the FUS group (p = 0.0030) and F&B&E group (p = 0.0208). HE staining results showed that nerve fibrinolysis, neuronal necrosis, microglia production, and erythrocytes were found in both the F&B group and the F&B&E group, but the areas of the nerve fibrinolysis and neuronal necrosis in the F&B group were larger than the F&B&E group. Conclusions A rat ICH model was successfully prepared using the μBs assisted FUS treatment, and edaravone had a therapeutic effect on this model. This model can be used to study the pathophysiological mechanism of ICH‐related diseases and in preclinical research on related new drugs.

Keywords